Joel Ackerman Sells 64,029 Shares of DaVita Inc. (NYSE:DVA) Stock

DaVita Inc. (NYSE:DVA) CFO Joel Ackerman sold 64,029 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total value of $9,928,336.74. Following the completion of the sale, the chief financial officer now directly owns 111,481 shares in the company, valued at $17,286,243.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

DaVita Trading Down 0.2 %

NYSE DVA traded down $0.34 on Thursday, hitting $153.24. The company’s stock had a trading volume of 654,976 shares, compared to its average volume of 823,127. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94. DaVita Inc. has a 1-year low of $71.51 and a 1-year high of $156.44. The company’s 50-day moving average is $142.05 and its 200 day moving average is $137.28. The firm has a market cap of $12.86 billion, a PE ratio of 17.34, a PEG ratio of 0.89 and a beta of 0.87.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.47 by $0.12. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.15 billion. During the same period in the prior year, the firm posted $2.08 EPS. The company’s quarterly revenue was up 6.2% on a year-over-year basis. As a group, analysts predict that DaVita Inc. will post 9.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DVA has been the topic of several research analyst reports. Barclays raised their price objective on DaVita from $133.00 to $150.00 and gave the company an “equal weight” rating in a research note on Monday, May 6th. Truist Financial raised their price objective on DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a research note on Tuesday, August 20th. Bank of America lifted their price target on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. Finally, TD Cowen lifted their target price on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, DaVita presently has an average rating of “Hold” and an average target price of $157.00.

Institutional Investors Weigh In On DaVita

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of DaVita by 2.4% in the 4th quarter. Vanguard Group Inc. now owns 6,320,740 shares of the company’s stock valued at $662,161,000 after purchasing an additional 145,711 shares during the last quarter. Gates Capital Management Inc. boosted its stake in DaVita by 3.1% during the fourth quarter. Gates Capital Management Inc. now owns 905,830 shares of the company’s stock worth $94,895,000 after acquiring an additional 27,660 shares in the last quarter. 8 Knots Management LLC bought a new position in DaVita during the fourth quarter worth $89,504,000. Allianz Asset Management GmbH boosted its stake in DaVita by 63.9% during the fourth quarter. Allianz Asset Management GmbH now owns 548,642 shares of the company’s stock worth $57,476,000 after acquiring an additional 213,992 shares in the last quarter. Finally, Doma Perpetual Capital Management LLC bought a new position in DaVita during the fourth quarter worth $53,076,000. 90.12% of the stock is owned by institutional investors.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.